Influenza A vaccine H1N1 - Zydus CadilaAlternative Names: VaxiFlu - S
Latest Information Update: 09 Mar 2017
At a glance
- Originator Zydus Cadila
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Influenza A virus H1N1 subtype